Results: Exomes were sequenced with an average base coverage of 117.9x, a mean of 93.5% of the target sequence was covered to a depth of at least 20x, and uniformity of base coverage was 92.7%. We identified a mean of 49.8 nonsynonymous mutations per sample (range 2-136) with RPM!1. We predicted a mean of 37.8 candidate epitopes/ sample (3-90) with binding affinity of less than 500nM with NetMHC. Conclusion: We have established a screening system of candidate cancer neoantigens whose immunogenecity should be further validated by the cytotoxic T lymphocytes (CTL) induction system. O2 À 5 À 5 Development of new photo-activated local cancer immunotherapy: targeting tumor infiltrating regulatory T cells
CD4þCD25þFoxp3þ regulatory T cells (Tregs) are known to suppress immune responses. Treg-mediated immunosuppression is a key mechanism for tumor immune-evasion, which could lead cancer immunotherapies to failures. Systemic depletion of Tregs has been tried by using antibodies against them; however, intravenously delivering these antibodies might not sufficiently deplete Tregs in tumor microenvironment or could deplete effector cells. Furthermore, systemic severe autoimmune responses could cause potential side effects. To address these problems, we exploited near infrared photoimmunotherapy (NIR-PIT) to deplete only intratumoral Tregs with anti-CD25-antibody aiming to induce anti-tumor immune activation within manageable side effects. NIR-PIT is a recently developed cancer treatment that combines the specificity of intravenously injected antibodies that target tumors/cells with the toxicity induced by photosensitizers activated by NIR-light. Depletion of intratumoral-Tregs with a local CD25-target-NIR-PIT rapidly induced CD8 T-and NK-cell activation, thereby restoring local anti-tumor immunity. Consequently, activated immunity led to regression of not only NIR-PIT-treatedtumors but also non-NIR-light-exposed-tumors in separate parts of the body (Abscopal Effect). These anti-tumor effects were partially CD8, NK, or INFg-dependent. Taken together, Local CD25-target-NIR-PIT depleted intratumoral T-regs, which modulated tumor-microenvironment to rapid rejection of tumors, and could activate other immune cells. Local CD25-target-NIR-PIT also induced antitumor-effect on distant non-irradiated tumor by rapid activation and cytotoxic action of CD8 T cells and NK cells. These observations suggest that local CD25-target-NIR-PIT may be a promising new strategy for cancer immunotherapy. This study suggests a promising new strategy for cancer immunotherapy.
O2 À 5 À 6 Neutrophil to lymphocyte ratio (NLR) as an early marker for outcome in patients treated with nivolumab in advanced NSCLC Aya Nakaya, Maiko Niki, Takashi Yokoi, Yuki Takeyasu, Kayoko Kibata, Makoto Ogata, Yoshitaro Torii, Takayasu Kurata, Shosaku Nomura Kansai Medical University
Background: There is an unmet need to identify markers predictive of response to nivolumab in patients with NSCLC because the number of responders to nivolumab is limited and its cost is very high. Recently, NLR has been recognized as a poor prognostic indicator in various cancers. Here we quantify the prognostic impact of NLR in NSCLC patients treated with nivolumab. Methods: We retrospectively analyzed 102 patients with advanced NSCLC treated with nivolumab at Kansai Medical University Hospital from December 2015 to December 2016. These patients have been administered nivolumab at a dose of 3 mg/kg every two weeks. The prognostic value of NLR for disease progression at baseline, 2 weeks and 4 weeks after nivolumab treatments were assessed. Results: The median age was 69 years old (51 to 84 years). Squamous cell carcinoma was 37% and non-squamous was 63%. The optimal cutoff for NLR was 3. Baseline NLR (HR 3.402, 95%CI: 1.418-8.161, p ¼ 0.006085), NLR at two weeks(HR 3.486, 95%CI: 1.303-9.328,p¼ 0.01288), and NLR at 4 weeks(HR 7.451, 95%CI: 2.203-25.21,p¼0.001237) were significantly associated with the outcome in terms of disease progression. Conclusion: NLR might be a useful marker at baseline and during treatment to predict early response or progression in patients with advanced NSCLC patients who receive nivolumab.
O2 À 6 À 1 Efficacy of anti-PD-1/PD-L1 antibody after discontinuation of antibody due to non-progressive disease in NSCLC Patients Hyogo Cancer Center Background: Immune checkpoint inhibitors (ICI) have emerged as promising therapeutic agents in non-small cell lung cancer (NSCLC). However, we're faced with the clinical problem until when we should continue ICI. Patients and Methods: We examined the efficacy of PD-1/PD-L1 inhibitors after discontinuation of antibody due to some reason except progressive disease (PD) in patients with NSCLC. This was a multicenter, retrospective study that analyzed NSCLC patients who were treated with PD-1/PD-L1 inhibitor by August 2016. The cut-off date for data collection was December 31, 2016. Results: The patients comprised of 17 males and 1 female, with the median age being 65 years old (49-80) . Histology indicated that 13 patients had squamous cell carcinoma, 4 patients had adenocarcinoma, and one patient had adenosquamous cell carcinoma. All patients had history of smoking (46.5 pack-years, range 12.5-116). 17 of 18 patients were treated with nivolumab, one was with atelolizumab. All patients had good Eastern Cooperative Oncology Group (ECOG) performance status (0 or 1). All the reasons for discontinuation of PD-1/PD-L1 inhibitors were treatment-related adverse events, nine of them was interstitial pneumonia. Thirteen patients (72.2%) were treated with steroid therapy. The median number of treatment cycles was 5 (range, 1-70) and the median duration of treatment was 2.3 months (range, 1 day-32.9 months). Best response was CR 1, PR 5, SD 11, and NE 1. The median progression-free survival (PFS) after discontinuation was 4.9 months (95% CI, 3.6-6.1 months). Nine patients were still followed up. Five of six responder (CRþPR) showed continuous remission after discontinuation of PD-1/PD-L1 inhibitor. Conclusion: It's still unclear that how many time of administration of PD-1/PD-L1 inhibitor is enough. But, some cases, especially the cases had CR or PR in the treatment, were disposed to show durable response after discontinuation of PD-1/PD-L1 inhibitors.
O2 À 6 À 2 Progression-free duration of NSCLC patients after cessation of Nivolumab Atsuto Mouri, Ou Yamaguti, Takahiro Uchida, Ayako Shiono, Harue Utugi, Fuyumi Nishihara, Yoshitake Murayama, Kunihiko Kobayashi, Hiroshi Kagamu Saitama Medical University International Medical Center
Background: An anti-PD-1 antibody, Nivolumab, has led to durable responses over 1 year in non-small cell carcinoma (NSCLC). Antitumor therapeutic efficacy could persist even after cessation of Nivolumab therapy because of invigorated antitumor T cells.
Methods: This study examined progression free duration and clinical characteristics of patients who once responded and discontinued Nivolumab therapy without tumor progression. Results: In total 76 patients who received Nivolumab therapy were evaluated by RECIST ver1.1. Twenty-one (27.6%) patients achieved CR/PR response. The median age was 70 (range, 54 to 84). ECOG PS 0, 1, or 2 was observed in 12, 5, 4 cases. Histologically, adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, not otherwise specified were observed in 9, 8, 1, 3 cases respectively. Nine of 21 patients discontinued Nivolumab therapy for reasons other than progressive disease. Seven patients had lung abnormal opacities as immune-related adverse event, 1 patient had abdominal wall bacterial infection, and 1 patient quitted because of patient will. Five patients with interstitial pneumonia with grade 2 were treated with corticosteroid by 0.5mg/kg. The median administration of Nivolumab was 5 (range, 1 to 12). The median progression-free survival period was 262 days, and the median progression-free duration after last administration of Nivolumab was 166 days at this report. Eight of 9 patients still have progression-free survival without any additional antitumor treatment. Conclusion: It is likely that antitumor T cells invigorated by Nivolumab therapy exhibited durable antitumor efficacy in the absence of Nivolumab, resulting in long progression-free duration after cessation of Nivolumab. 
